{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T05:42:40Z","timestamp":1768801360860,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81330079"],"award-info":[{"award-number":["81330079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573446"],"award-info":[{"award-number":["81573446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.taap.2018.09.044","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T11:05:35Z","timestamp":1538478335000},"page":"249-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"360","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elgehama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2018.09.044_bb0005","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1038\/ncomms9859","article-title":"Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis","volume":"6","author":"Bunda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2018.09.044_bb0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2018.09.044_bb0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2006-04-019141","article-title":"SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl","volume":"109","author":"Chen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0020","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.taap.2018.09.044_bb0030","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0035","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2018.09.044_bb0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2015.12.014","article-title":"Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells","volume":"372","author":"Elgehama","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.taap.2018.09.044_bb0045","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.taap.2018.09.044_bb0050","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1182\/blood-2011-03-341073","article-title":"SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia","volume":"118","author":"Esposito","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.159","article-title":"Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells","volume":"8","author":"Gao","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.taap.2018.09.044_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0092-8674(95)90277-5","article-title":"Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene","volume":"82","author":"Goga","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.taap.2018.09.044_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2017.250","article-title":"SHP2 is required for BCR-ABL1-induced hematologic neoplasia","volume":"32","author":"Gu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2018.09.044_bb0070","doi-asserted-by":"crossref","first-page":"29679","DOI":"10.18632\/oncotarget.11425","article-title":"CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia","volume":"8","author":"Guerra","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2018.09.044_bb0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.taap.2018.09.044_bb0080","first-page":"371","article-title":"Effect of ZD6474 on the proliferation of imatinib-resistant K562 cells","volume":"31","author":"Jia","year":"2010","journal-title":"Zhonghua xue ye xue za zhi"},{"key":"10.1016\/j.taap.2018.09.044_bb0085","first-page":"970","article-title":"Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells","volume":"1","author":"Kirschner","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.taap.2018.09.044_bb0090","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0095","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/bph.12565","article-title":"Blocking initial infiltration of pioneer CD8(+) T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice","volume":"171","author":"Luo","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2018.09.044_bb0100","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0105","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.leukres.2013.07.013","article-title":"Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and gamma-catenin inhibition","volume":"37","author":"Niu","year":"2013","journal-title":"Leuk. Res."},{"key":"10.1016\/j.taap.2018.09.044_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1634\/stemcells.21-3-315","article-title":"Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22\/SR","volume":"21","author":"Ohmine","year":"2003","journal-title":"Stem Cells"},{"key":"10.1016\/j.taap.2018.09.044_bb0115","doi-asserted-by":"crossref","first-page":"25345","DOI":"10.1074\/jbc.M400590200","article-title":"Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells","volume":"279","author":"Parmar","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2018.09.044_bb0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.taap.2018.09.044_bb0125","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2018.09.044_bb0130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.taap.2018.09.044_bb0135","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.taap.2018.09.044_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.taap.2018.09.044_bb0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.taap.2018.09.044_bb0150","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2018.09.044_bb0155","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-17-1904","article-title":"ER stress signaling promotes the survival of cancer \"persister cells\" tolerant to EGFR tyrosine kinase inhibitors","volume":"78","author":"Terai","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2018.09.044_bb0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.phrs.2015.09.022","article-title":"AKT inactivation causes persistent drug tolerance to EGFR inhibitors","volume":"102","author":"Tetsu","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.taap.2018.09.044_bb0165","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/jid.2014.252","article-title":"Trichomide A, a natural cyclodepsipeptide, exerts immunosuppressive activity against activated T lymphocytes by upregulating SHP2 activation to overcome contact dermatitis","volume":"134","author":"Wang","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.taap.2018.09.044_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijbs.22209","article-title":"Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression","volume":"14","author":"Wang","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.taap.2018.09.044_bb0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/leu.2012.222","article-title":"Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors","volume":"27","author":"Wohrle","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.taap.2018.09.044_bb0180","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2013.09.028","article-title":"Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma","volume":"439","author":"Xu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2018.09.044_bb0185","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.taap.2018.09.044_bb0190","doi-asserted-by":"crossref","first-page":"12226","DOI":"10.1074\/jbc.M900020200","article-title":"Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation","volume":"284","author":"Zhou","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2018.09.044_bb0195","first-page":"1903","article-title":"Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia","volume":"85","author":"Zhu","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18304587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X18304587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T03:26:13Z","timestamp":1571973973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X18304587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"alternative-id":["S0041008X18304587"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2018.09.044","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2018.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}